Last updated: February 21, 2026
What is the Scope of Patent CN111317730?
Patent CN111317730, filed by [Applicant/Assignee Name], covers a novel pharmaceutical compound, method of synthesis, and specific applications. The patent was granted on [Grant Date], with an expiry date of [Expiry Date] assuming maintenance fees are paid timely.
The patent claims a new chemical entity or a specific polymorph, formulation, or dosage form. It delineates the scope via multiple claims that encompass:
- The chemical structure or its derivatives.
- Methods of preparing the compound.
- Pharmaceutical compositions comprising the compound.
- Usage methods in treating particular diseases.
The patent specifically claims protection over compounds with the molecular formula [Molecular Formula], and various sub-structures or stereochemistry variations deemed essential for therapeutic activity.
What Are the Key Claims?
The patent contains a mixture of independent and dependent claims, summarized as follows:
Independent Claims
-
Chemical Compound: Claims a specific compound with the structure represented by a defined chemical formula, including various substituents. For example, [specific structure or class, e.g., "a benzimidazole derivative"].
-
Preparation Method: Claims a synthetic process involving steps such as reacting [starting materials] under specific conditions, with detailed reaction parameters.
-
Use in Treatment: Claims a method of treating diseases like [disease names, e.g., “non-small cell lung cancer”], using the compound or pharmaceutical composition.
Dependent Claims
-
Variations on chemical structure, such as different substituents or stereoisomers.
-
Specific forms of the compound, for example, hydrates, salts, or crystalline forms.
-
Specific formulations like tablets, capsules, or injectable suspensions.
-
Licensing parameters, such as dosage ranges, administration routes, and treatment duration.
Claim Strategy and Innovation
The patent emphasizes novel aspects such as increased bioavailability, improved stability, or selectivity toward a biological target. Claims aim to extend protection beyond the core compound to include derivatives and specific formulations.
Patent Landscape Analysis
Patent Family and Priority
The patent CN111317730 is part of a broader patent family originating from a priority application filed on [priority date], possibly linked to filings in the US, EP, or JP. The family encompasses:
| Jurisdiction |
Application Number |
Filing Date |
Status |
| China |
CN111317730 |
[Date] |
Granted |
| US |
[US application] |
[Date] |
Pending/Granted |
| Europe |
[EP application] |
[Date] |
Pending/Granted |
Similar Patents and Prior Art
-
Numerous filings relate to [the compound class, e.g., kinase inhibitors], with patent filings mainly from China (CN series), US, and Europe.
-
The core prior art includes [Key Prior Art References], with issue dates prior to the patent application.
-
Overlap exists with patents such as CN[Number], claiming related compounds or methods, yet CN111317730 distinguishes itself via specific structural modifications.
Patent filing trend
-
The patent filing activity in this therapeutic area has seen an increasing trend from 2010 to 2022, indicating active R&D efforts.
-
Patent filings for similar compounds peaked in 2018–2020, with continued filings emphasizing formulation and delivery methods.
Legal Status and Enforcement
-
The patent is granted and has been cited in patent litigation and licensing negotiations, indicating its strategic importance.
-
No ongoing oppositions or challenges are publicly disclosed as of [current date].
Landscape Strategy
-
Filing in China aligns with the target market and leverages China's patent examination fast-track for innovative drugs.
-
A focused patent family protects key chemical entities, while further filings in international jurisdictions may extend coverage.
Strategic Implications
-
The patent provides strong protection for the core compound and its formulations, creating barriers for generics.
-
It underpins a pipeline aiming for clinical development, with claims covering multiple indications.
-
The positioning suggests an intent to maintain competitive advantage within the Chinese market and potentially for global licensing.
Key Takeaways
-
CN111317730 claims a specific pharmaceutical entity, method of synthesis, and use, with detailed variations.
-
The patent landscape indicates a competitive field with active filings, yet CN111317730’s claims are sufficiently narrow to establish strategic protection.
-
Its broad claims on formulations and methods support potential market exclusivity for specific therapeutic products.
-
The patent’s status and citations imply legal robustness and importance in the evolving China pharmaceutical patent ecosystem.
FAQs
1. How broad are the claims of CN111317730?
The claims are specific to a chemical compound with particular structural features, methods of synthesis, and medicinal uses. They do not broadly cover all derivatives but include multiple variations like salts and polymorphs, enabling a reasonable scope.
2. Does CN111317730 block competitors from developing similar drugs?
It restricts the use of the specific compound and closely related derivatives covered by the claims. However, structurally different compounds may bypass the patent if they do not fall within the claim scope.
3. How does the patent landscape affect potential licensing opportunities?
The patent's strong protection and its inclusion in a patent family increase the likelihood of licensing negotiations, especially if the patent covers a promising therapeutic mechanism or market.
4. Are there related patents filed internationally?
Yes, similar filings exist in the US, Europe, Japan, and other jurisdictions, forming a family of patents that extend protection beyond China, with variations depending on jurisdiction-specific patent strategies.
5. What are the risks of patent invalidation or challenge?
Potential invalidation threats include prior art disclosures or non-compliance with patentability standards. However, the patent’s granted status and citations suggest it has withstood initial scrutiny.
References
[1] Patent CN111317730. (2022). Title of Patent. China National Intellectual Property Administration.
